Jan 8, 2026 07:34AM
Jan 8, 2026 07:34AM
Nov 13, 2025 05:00PM
Nov 13, 2025 05:00PM
Nov 4, 2025 04:39PM
Sep 29, 2025 05:00PM
Sep 29, 2025 05:00PM Eupraxia Pharmaceuticals Announces Positive Data from Highest-Dose Cohort in the Ongoing RESOLVE Trial in Eosinophilic Esophagitis, and Plans for Expansion of EP-104GI Development Programs
Sep 2, 2025 08:02AM
Sep 2, 2025 08:00AM
Sep 2, 2025 08:00AM
Aug 12, 2025 04:25PM
Jul 22, 2025 05:17PM
Jul 8, 2025 07:00AM
Jul 8, 2025 07:00AM Eupraxia Doses First Patient in Phase 2b Placebo-Controlled Portion of EP-104GI RESOLVE Trial in Eosinophilic Esophagitis
Jun 2, 2025 06:30PM
May 7, 2025 02:00PM
May 6, 2025 06:00PM
May 5, 2025 07:00AM
Apr 24, 2025 05:00PM
Mar 20, 2025 05:32PM
Feb 25, 2025 07:01AM Eupraxia Pharmaceuticals (EPRX) Announces Positive Data from RESOLVE Phase 1b/2a Trial of EP-104GI
Feb 25, 2025 07:00AM
Feb 18, 2025 07:00AM
Feb 18, 2025 07:00AM
Nov 20, 2024 07:00AM
Nov 14, 2024 05:00PM
Nov 13, 2024 05:00PM
Nov 12, 2024 05:56PM Eupraxia Pharmaceuticals Announces Positive Data from Fifth Cohort of RESOLVE Phase 1b/2a Trial of EP-104GI for Treatment of Eosinophilic Esophagitis
Oct 31, 2024 07:36PM
Oct 28, 2024 07:00AM
Oct 15, 2024 07:00AM
Oct 15, 2024 07:00AM
Oct 10, 2024 07:00AM
Oct 2, 2024 05:01PM
Oct 2, 2024 05:01PM Eupraxia Pharmaceuticals Strengthens Senior Management Team
Sep 19, 2024 05:00PM
Sep 11, 2024 07:01AM
Sep 11, 2024 07:00AM
Aug 7, 2024 05:00PM
May 8, 2024 05:03PM
May 2, 2024 07:00AM
Apr 1, 2024 05:01PM Eupraxia Pharmaceuticals Reports Fourth Quarter and 2023 Financial Results
Jun 26, 2023 07:00AM

312,667 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All